Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2361${count})

  • Research Grant, 2016
    Rab Detection Initiative

    Study Rationale:
    The LRRK2 enzyme regulates proteins through a process called phosphorylation. The LRRK2 gene, which is mutated in familial Parkinson's disease (PD), an inherited form of PD, can...

  • Target Advancement Program, 2016
    Protecting Dopamine Neurons in Parkinson's Disease

    Study Rationale:
    Parkinson's disease (PD) is caused by death of dopamine-containing cells in the brain. We discovered that a protein known as RGS6 is expressed in these cells in pre-clinical models of...

  • Target Advancement Program, 2016
    Imaging Endogenous LRRK2 Cells

    Study Rationale:
    The leucine-rich repeat kinase 2 (LRRK2) protein is an important player that contributes to Parkinson's disease (PD). Unfortunately, LRRK2 is a large and complex protein that is...

  • Access to Data and Biospecimens, 2016
    Single Molecule Detection of Oligomers in Cerebrospinal Fluid

    Study Rationale:
    We have developed a novel method for detecting aggregations (clumps) of proteins (specifically, alpha-synuclein) in the spinal fluid of those with Parkinson's disease (PD). We seek to...

  • Therapeutic Pipeline Program, 2016
    Small-molecule Inhibitor to Stop Alpha-synuclein Spread for the Treatment of Parkinson's Disease

    Study Rationale:
    The hypothesis that misfolded alpha-synuclein (a protein associated with Parkinson's) aggregates (clumps) move from neuron-to-neuron is gaining widespread acceptance as a central...

  • Research Grant, 2016
    Planning Phase for a Phase IIa Study of Nilotinib in People with Parkinson's Disease

    Study Rationale:

    Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.